BR112016010383A2 - compostos de pyy seletivos e usos dos mesmos - Google Patents

compostos de pyy seletivos e usos dos mesmos

Info

Publication number
BR112016010383A2
BR112016010383A2 BR112016010383A BR112016010383A BR112016010383A2 BR 112016010383 A2 BR112016010383 A2 BR 112016010383A2 BR 112016010383 A BR112016010383 A BR 112016010383A BR 112016010383 A BR112016010383 A BR 112016010383A BR 112016010383 A2 BR112016010383 A2 BR 112016010383A2
Authority
BR
Brazil
Prior art keywords
pyy compounds
compounds
selective
hpyy
relates
Prior art date
Application number
BR112016010383A
Other languages
English (en)
Inventor
Wieczorek Birgit
Schjellerup Wulff Birgitte
Jessen Carsten
Kaalby Thomsen Jens
Waldemar Conde Frieboes Kilian
Østergaard Søren
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR112016010383A2 publication Critical patent/BR112016010383A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

a presente invenção refere-se a compostos de pyy que têm o aminoácido na posição que corresponde à posição 30 de hpyy(1-36) substituído por triptofano e derivados do mesmo com um grupo de modificação fixado à posição que corresponde à posição 7 de hpyy(1-36). os compostos da invenção são agonistas de receptor de y2 seletivos. a invenção também se refere a composições farmacêuticas que compreendem tais compostos de pyy e excipientes farmaceuticamente aceitáveis, assim como o uso médico dos compostos de pyy.
BR112016010383A 2013-11-15 2014-11-13 compostos de pyy seletivos e usos dos mesmos BR112016010383A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP13193082 2013-11-15
US201361906020P 2013-11-19 2013-11-19
EP14176725 2014-07-11
PCT/EP2014/074476 WO2015071355A1 (en) 2013-11-15 2014-11-13 Selective pyy compounds and uses thereof

Publications (1)

Publication Number Publication Date
BR112016010383A2 true BR112016010383A2 (pt) 2017-12-05

Family

ID=53056816

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016010383A BR112016010383A2 (pt) 2013-11-15 2014-11-13 compostos de pyy seletivos e usos dos mesmos

Country Status (15)

Country Link
US (2) US10246497B2 (pt)
EP (1) EP3068421B1 (pt)
JP (1) JP6602760B2 (pt)
KR (1) KR20160075819A (pt)
CN (1) CN105722526B (pt)
AU (1) AU2014350197B2 (pt)
BR (1) BR112016010383A2 (pt)
CA (1) CA2929672A1 (pt)
IL (1) IL245045B (pt)
MX (1) MX369818B (pt)
PL (1) PL3068421T3 (pt)
RS (1) RS59026B1 (pt)
SI (1) SI3068421T1 (pt)
TW (1) TWI661835B (pt)
WO (1) WO2015071355A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013014942B1 (pt) 2010-12-16 2020-01-28 Novo Nordisk As composições sólidas para administração, e seus usos
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
AU2014261111B2 (en) * 2013-05-02 2017-03-16 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
WO2015071356A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
AU2016275735B2 (en) * 2015-06-12 2020-02-06 Novo Nordisk A/S Selective PYY compounds and uses thereof
RU2768283C2 (ru) * 2016-04-28 2022-03-23 Ново Нордиск А/С Семаглутид при сердечно-сосудистых состояниях
WO2018083335A1 (en) 2016-11-07 2018-05-11 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
EP3655426A1 (en) 2017-07-19 2020-05-27 Novo Nordisk A/S Egf(a) analogues, preparation, formulations and uses thereof
WO2019106193A1 (en) 2017-12-01 2019-06-06 University Of Copenhagen Peptide hormone with one or more o-glycans
AU2019206391A1 (en) * 2018-01-09 2020-07-16 Gila Therapeutics, Inc Compositions and methods for treating metabolic diseases
PL3746111T3 (pl) 2018-02-02 2024-01-15 Novo Nordisk A/S Stałe kompozycje zawierające agonistę glp-1 i sól kwasu n-(8-(2- hydroksybenzoilo)amino kaprylowego i substancję poślizgową
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
TWI749381B (zh) 2018-11-01 2021-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
WO2021023817A1 (en) * 2019-08-07 2021-02-11 Novo Nordisk A/S Solid composition comprising a pyy compound and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
AU2020384729A1 (en) 2019-11-11 2022-04-14 Boehringer Ingelheim International Gmbh NPY2 receptor agonists
WO2022029231A1 (en) 2020-08-07 2022-02-10 Boehringer Ingelheim International Gmbh Soluble npy2 receptor agonists
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960701653A (ko) 1993-03-29 1996-03-28 발라수브라마니암 엠비카이파칸 펩타이드 yy의 유사체 및 그의 용도
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
AU1159897A (en) 1996-11-13 1998-06-03 University Of Cincinnati, The Analogs of peptide yy and uses thereof
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
EP1086078B1 (en) 1998-06-08 2003-02-05 Schering Corporation Neuropeptide y5 receptor antagonists
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
BR0116206A (pt) 2000-12-14 2003-12-23 Amylin Pharmaceuticals Inc Peptìdeo yy e agonistas de peptìdeo yy para tratamento de distúrbios metabólicos
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
EP2050460A1 (en) 2001-09-24 2009-04-22 Imperial Innovations Limited PYY and agonists thereof for modification of feeding behaviour
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP1583549A4 (en) 2003-01-17 2006-10-04 Sod Conseils Rech Applic YY PEPTIDE ANALOGS
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
EP2932981B1 (en) 2003-09-19 2021-06-16 Novo Nordisk A/S Albumin-binding derivatives of GLP-1
TW200522976A (en) 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
BRPI0417684A (pt) 2003-12-18 2007-03-20 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
JP5638177B2 (ja) 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
WO2005077072A2 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1807099A2 (en) 2004-03-17 2007-07-18 7TM Pharma A/S Y2 selective receptor agonists for therapeutic interventions
EP2057996A3 (en) 2004-03-17 2009-11-04 7TM Pharma A/S Y4 selective receptor agonists for therapeutic intervention
BRPI0508861A (pt) 2004-03-17 2007-08-28 7Tm Pharmas As agonistas do receptor y2/y4 seletivo para intervenções terapêuticas
CN100425282C (zh) 2004-03-17 2008-10-15 7Tm制药联合股份有限公司 用于治疗性干预的y2/y4选择性受体激动剂
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2006005667A2 (en) 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
WO2006020207A2 (en) 2004-07-19 2006-02-23 University Of Cincinnati Compounds for control of appetite
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
CA2614619A1 (en) 2005-07-11 2007-01-18 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
MX2007016024A (es) 2005-07-18 2008-03-10 Novo Nordisk As Peptidos novedosos para el uso en el tratamiento contra la obesidad.
CA2623088A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
US7851590B2 (en) 2005-09-21 2010-12-14 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
ES2381497T3 (es) 2005-12-07 2012-05-28 F. Hoffmann-La Roche Ag Agonistas del receptor del neuropéptido-2
WO2007068718A1 (en) 2005-12-14 2007-06-21 Novo Nordisk A/S Polypeptide protracting tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
AU2007227202B2 (en) 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
JP2010516652A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
RU2506273C2 (ru) 2007-07-09 2014-02-10 Импиэриэл Инноувейшнс Лимитид Аналог панкреатического полипептида человека (варианты), фармацевтическая композиция на его основе, способ лечения ожирения или диабета, способ снижения аппетита, уменьшения поглощения пищи или снижения потребления калорий и способ косметического снижения массы посредством указанного аналога
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100210559A1 (en) * 2007-09-11 2010-08-19 Mondobiotech Laboratories Ag Trap-14 as a therapeutic agent
US8598314B2 (en) 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
KR20110017874A (ko) 2008-05-16 2011-02-22 노보 노르디스크 에이/에스 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
JP2012507487A (ja) 2008-11-05 2012-03-29 エフ．ホフマン−ラ ロシュ アーゲー 神経ペプチド２受容体（ｙ−２ｒ）アゴニスト及びその使用
CN102325545A (zh) 2009-02-20 2012-01-18 益普生制药股份有限公司 具有神经肽y受体结合化合物的细胞毒性缀合物
CN102573888A (zh) * 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
WO2011045232A2 (en) 2009-10-13 2011-04-21 F. Hoffmann-La Roche Ag Neuropeptide-2 receptor (y-2r) agonists
WO2011058165A1 (en) 2009-11-13 2011-05-19 Novo Nordisk A/S Long-acting y2 receptor agonists
US9040660B2 (en) 2010-04-20 2015-05-26 Novo Nordisk A/S Long-acting gastrin derivatives
AU2011249722B2 (en) * 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
EP2855517A1 (en) 2012-05-29 2015-04-08 Novo Nordisk A/S Pancreatic polypeptide compounds and use
AU2014261111B2 (en) 2013-05-02 2017-03-16 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
WO2015071356A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
MX369818B (es) 2013-11-15 2019-11-22 Novo Nordisk As Compuestos selectivos de peptido yy (pyy) y usos de los mismos.
AU2016275735B2 (en) * 2015-06-12 2020-02-06 Novo Nordisk A/S Selective PYY compounds and uses thereof

Also Published As

Publication number Publication date
US10246497B2 (en) 2019-04-02
US20160289283A1 (en) 2016-10-06
TWI661835B (zh) 2019-06-11
SI3068421T1 (sl) 2019-08-30
EP3068421B1 (en) 2019-04-17
IL245045B (en) 2019-09-26
JP6602760B2 (ja) 2019-11-06
RS59026B1 (sr) 2019-08-30
EP3068421A1 (en) 2016-09-21
US9085637B2 (en) 2015-07-21
AU2014350197A1 (en) 2016-05-05
US20150152150A1 (en) 2015-06-04
KR20160075819A (ko) 2016-06-29
MX2016006053A (es) 2016-08-17
JP2017505284A (ja) 2017-02-16
CN105722526B (zh) 2020-12-08
AU2014350197B2 (en) 2018-10-04
PL3068421T3 (pl) 2019-11-29
CA2929672A1 (en) 2015-05-21
CN105722526A (zh) 2016-06-29
MX369818B (es) 2019-11-22
IL245045A0 (en) 2016-05-31
TW201605467A (zh) 2016-02-16
WO2015071355A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
BR112016010383A2 (pt) compostos de pyy seletivos e usos dos mesmos
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
BR112016016844A2 (pt) Compostos heterocíclicos
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
CL2013002414A1 (es) Compuestos derivados de azabencimidazol ciclico, activadores de la proteina cinasa activada por amp; composicion farmaceutica que los comprende; y su uso para el tratamiento o enfermedad tal como diabetes tipo 2, hiperglicemia, sindrome metabolico, obesidad, hipercolesterolemia e hipertension.
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112015011031A2 (pt) moduladores de grp40 de di-hidropirazol
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
BR112016030733A2 (pt) Derivados de indano e indolina e uso dos mesmos como ativadores de guanilato ciclase solúveis
BR112017018305A2 (pt) desacetoxitubulisina h e análogos da mesma
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
BR112015017251A8 (pt) composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
BR112015030387A2 (pt) compostos de pirazol como moduladores de fshr e usos dos mesmos
CL2018000529A1 (es) Compuestos heteroarilo y su uso como fármacos terapéuticos.
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
BR112017026272A2 (pt) ?composto, composição farmacêutica, método para o tratamento de uma desordem relacionada a receptor m1 muscarínico e uso do composto?
BR112017004948A2 (pt) formulação farmacêutica.
BR112013030391A2 (pt) derivados de piperidina 3- espirocíclicos como agonistas dos receptores de grelina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B10A Cessation: cessation confirmed